Cargando…
Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
Oxidative stress caused by free radicals has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone (also known as MCI-186), a free radical scavenger, was approved as an ALS treatment in 2015 in Japan. However, the therapeutic effects of edaravone on patients with ALS...
Autores principales: | Park, Jin-Mo, Kim, Sun-Young, Park, Donghwi, Park, Jin-Sung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223963/ https://www.ncbi.nlm.nih.gov/pubmed/31471712 http://dx.doi.org/10.1007/s10072-019-04055-3 |
Ejemplares similares
-
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022) -
Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023) -
Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018) -
Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022) -
Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)